Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Foralumab Extension in Non-Active SPMS
NCT06890923Phase 2Recruiting
- Sponsor
- Tiziana Life Sciences
- Start
- Mar 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of foralumab in secondary-progressive multiple sclerosis (SPMS), sponsored by Tiziana Life Sciences. Started Mar 2025; status: recruiting.
02
Drugs
foralumab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT06890923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890923.